Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Identifieur interne : 001232 ( Main/Corpus ); précédent : 001231; suivant : 001233Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Auteurs : Dora Pinto ; Young-Jun Park ; Martina Beltramello ; Alexandra C. Walls ; M Alejandra Tortorici ; Siro Bianchi ; Stefano Jaconi ; Katja Culap ; Fabrizia Zatta ; Anna De Marco ; Alessia Peter ; Barbara Guarino ; Roberto Spreafico ; Elisabetta Cameroni ; James Brett Case ; Rita E. Chen ; Colin Havenar-Daughton ; Gyorgy Snell ; Amalio Telenti ; Herbert W. Virgin ; Antonio Lanzavecchia ; Michael S. Diamond ; Katja Fink ; David Veesler ; Davide CortiSource :
- Nature [ 1476-4687 ] ; 2020.
English descriptors
- KwdEn :
- Animals (MeSH), Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacology), Antibodies, Neutralizing (chemistry), Antibodies, Neutralizing (immunology), Antibodies, Neutralizing (pharmacology), Antibodies, Viral (chemistry), Antibodies, Viral (immunology), Antibodies, Viral (pharmacology), Antibody-Dependent Cell Cytotoxicity (drug effects), Antibody-Dependent Cell Cytotoxicity (immunology), B-Lymphocytes (immunology), Betacoronavirus (chemistry), Betacoronavirus (drug effects), Betacoronavirus (immunology), Chlorocebus aethiops (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Coronavirus Infections (virology), Cross Reactions (drug effects), Cross Reactions (immunology), Cryoelectron Microscopy (MeSH), Epitopes, B-Lymphocyte (chemistry), Epitopes, B-Lymphocyte (immunology), HEK293 Cells (MeSH), Humans (MeSH), Immune Evasion (immunology), Immunoglobulin Fab Fragments (chemistry), Immunoglobulin Fab Fragments (immunology), Immunoglobulin Fab Fragments (pharmacology), Immunologic Memory (immunology), Killer Cells, Natural (drug effects), Killer Cells, Natural (immunology), Models, Molecular (MeSH), Neutralization Tests (MeSH), Pandemics (prevention & control), Peptidyl-Dipeptidase A (chemistry), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (immunology), Pneumonia, Viral (prevention & control), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), SARS Virus (chemistry), SARS Virus (drug effects), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (chemistry), Spike Glycoprotein, Coronavirus (immunology), Vero Cells (MeSH).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, B-Lymphocyte, Immunoglobulin Fab Fragments, Peptidyl-Dipeptidase A, Spike Glycoprotein, Coronavirus.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, B-Lymphocyte, Immunoglobulin Fab Fragments, Spike Glycoprotein, Coronavirus.
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemistry : Betacoronavirus, SARS Virus.
- drug effects : Antibody-Dependent Cell Cytotoxicity, Betacoronavirus, Cross Reactions, Killer Cells, Natural, SARS Virus.
- immunology : Antibody-Dependent Cell Cytotoxicity, B-Lymphocytes, Betacoronavirus, Coronavirus Infections, Cross Reactions, Immune Evasion, Immunologic Memory, Killer Cells, Natural, Pneumonia, Viral, SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral, Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Cryoelectron Microscopy, HEK293 Cells, Humans, Models, Molecular, Neutralization Tests, Vero Cells.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
DOI: 10.1038/s41586-020-2349-y
PubMed: 32422645
Links to Exploration step
pubmed:32422645Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</title>
<author><name sortKey="Pinto, Dora" sort="Pinto, Dora" uniqKey="Pinto D" first="Dora" last="Pinto">Dora Pinto</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Park, Young Jun" sort="Park, Young Jun" uniqKey="Park Y" first="Young-Jun" last="Park">Young-Jun Park</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beltramello, Martina" sort="Beltramello, Martina" uniqKey="Beltramello M" first="Martina" last="Beltramello">Martina Beltramello</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Walls, Alexandra C" sort="Walls, Alexandra C" uniqKey="Walls A" first="Alexandra C" last="Walls">Alexandra C. Walls</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bianchi, Siro" sort="Bianchi, Siro" uniqKey="Bianchi S" first="Siro" last="Bianchi">Siro Bianchi</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jaconi, Stefano" sort="Jaconi, Stefano" uniqKey="Jaconi S" first="Stefano" last="Jaconi">Stefano Jaconi</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Culap, Katja" sort="Culap, Katja" uniqKey="Culap K" first="Katja" last="Culap">Katja Culap</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zatta, Fabrizia" sort="Zatta, Fabrizia" uniqKey="Zatta F" first="Fabrizia" last="Zatta">Fabrizia Zatta</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Marco, Anna" sort="De Marco, Anna" uniqKey="De Marco A" first="Anna" last="De Marco">Anna De Marco</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peter, Alessia" sort="Peter, Alessia" uniqKey="Peter A" first="Alessia" last="Peter">Alessia Peter</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guarino, Barbara" sort="Guarino, Barbara" uniqKey="Guarino B" first="Barbara" last="Guarino">Barbara Guarino</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Spreafico, Roberto" sort="Spreafico, Roberto" uniqKey="Spreafico R" first="Roberto" last="Spreafico">Roberto Spreafico</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Case, James Brett" sort="Case, James Brett" uniqKey="Case J" first="James Brett" last="Case">James Brett Case</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Havenar Daughton, Colin" sort="Havenar Daughton, Colin" uniqKey="Havenar Daughton C" first="Colin" last="Havenar-Daughton">Colin Havenar-Daughton</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Snell, Gyorgy" sort="Snell, Gyorgy" uniqKey="Snell G" first="Gyorgy" last="Snell">Gyorgy Snell</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Telenti, Amalio" sort="Telenti, Amalio" uniqKey="Telenti A" first="Amalio" last="Telenti">Amalio Telenti</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Virgin, Herbert W" sort="Virgin, Herbert W" uniqKey="Virgin H" first="Herbert W" last="Virgin">Herbert W. Virgin</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fink, Katja" sort="Fink, Katja" uniqKey="Fink K" first="Katja" last="Fink">Katja Fink</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Veesler, David" sort="Veesler, David" uniqKey="Veesler D" first="David" last="Veesler">David Veesler</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32422645</idno>
<idno type="pmid">32422645</idno>
<idno type="doi">10.1038/s41586-020-2349-y</idno>
<idno type="wicri:Area/Main/Corpus">001232</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001232</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</title>
<author><name sortKey="Pinto, Dora" sort="Pinto, Dora" uniqKey="Pinto D" first="Dora" last="Pinto">Dora Pinto</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Park, Young Jun" sort="Park, Young Jun" uniqKey="Park Y" first="Young-Jun" last="Park">Young-Jun Park</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beltramello, Martina" sort="Beltramello, Martina" uniqKey="Beltramello M" first="Martina" last="Beltramello">Martina Beltramello</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Walls, Alexandra C" sort="Walls, Alexandra C" uniqKey="Walls A" first="Alexandra C" last="Walls">Alexandra C. Walls</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bianchi, Siro" sort="Bianchi, Siro" uniqKey="Bianchi S" first="Siro" last="Bianchi">Siro Bianchi</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jaconi, Stefano" sort="Jaconi, Stefano" uniqKey="Jaconi S" first="Stefano" last="Jaconi">Stefano Jaconi</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Culap, Katja" sort="Culap, Katja" uniqKey="Culap K" first="Katja" last="Culap">Katja Culap</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zatta, Fabrizia" sort="Zatta, Fabrizia" uniqKey="Zatta F" first="Fabrizia" last="Zatta">Fabrizia Zatta</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Marco, Anna" sort="De Marco, Anna" uniqKey="De Marco A" first="Anna" last="De Marco">Anna De Marco</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peter, Alessia" sort="Peter, Alessia" uniqKey="Peter A" first="Alessia" last="Peter">Alessia Peter</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guarino, Barbara" sort="Guarino, Barbara" uniqKey="Guarino B" first="Barbara" last="Guarino">Barbara Guarino</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Spreafico, Roberto" sort="Spreafico, Roberto" uniqKey="Spreafico R" first="Roberto" last="Spreafico">Roberto Spreafico</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Case, James Brett" sort="Case, James Brett" uniqKey="Case J" first="James Brett" last="Case">James Brett Case</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Havenar Daughton, Colin" sort="Havenar Daughton, Colin" uniqKey="Havenar Daughton C" first="Colin" last="Havenar-Daughton">Colin Havenar-Daughton</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Snell, Gyorgy" sort="Snell, Gyorgy" uniqKey="Snell G" first="Gyorgy" last="Snell">Gyorgy Snell</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Telenti, Amalio" sort="Telenti, Amalio" uniqKey="Telenti A" first="Amalio" last="Telenti">Amalio Telenti</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Virgin, Herbert W" sort="Virgin, Herbert W" uniqKey="Virgin H" first="Herbert W" last="Virgin">Herbert W. Virgin</name>
<affiliation><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name>
<affiliation><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fink, Katja" sort="Fink, Katja" uniqKey="Fink K" first="Katja" last="Fink">Katja Fink</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Veesler, David" sort="Veesler, David" uniqKey="Veesler D" first="David" last="Veesler">David Veesler</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature</title>
<idno type="eISSN">1476-4687</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antibodies, Monoclonal (chemistry)</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antibodies, Neutralizing (chemistry)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Neutralizing (pharmacology)</term>
<term>Antibodies, Viral (chemistry)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (pharmacology)</term>
<term>Antibody-Dependent Cell Cytotoxicity (drug effects)</term>
<term>Antibody-Dependent Cell Cytotoxicity (immunology)</term>
<term>B-Lymphocytes (immunology)</term>
<term>Betacoronavirus (chemistry)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Chlorocebus aethiops (MeSH)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cross Reactions (drug effects)</term>
<term>Cross Reactions (immunology)</term>
<term>Cryoelectron Microscopy (MeSH)</term>
<term>Epitopes, B-Lymphocyte (chemistry)</term>
<term>Epitopes, B-Lymphocyte (immunology)</term>
<term>HEK293 Cells (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immune Evasion (immunology)</term>
<term>Immunoglobulin Fab Fragments (chemistry)</term>
<term>Immunoglobulin Fab Fragments (immunology)</term>
<term>Immunoglobulin Fab Fragments (pharmacology)</term>
<term>Immunologic Memory (immunology)</term>
<term>Killer Cells, Natural (drug effects)</term>
<term>Killer Cells, Natural (immunology)</term>
<term>Models, Molecular (MeSH)</term>
<term>Neutralization Tests (MeSH)</term>
<term>Pandemics (prevention & control)</term>
<term>Peptidyl-Dipeptidase A (chemistry)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS Virus (chemistry)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus (chemistry)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vero Cells (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Immunoglobulin Fab Fragments</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Epitopes, B-Lymphocyte</term>
<term>Immunoglobulin Fab Fragments</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Betacoronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Antibody-Dependent Cell Cytotoxicity</term>
<term>Betacoronavirus</term>
<term>Cross Reactions</term>
<term>Killer Cells, Natural</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody-Dependent Cell Cytotoxicity</term>
<term>B-Lymphocytes</term>
<term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Cross Reactions</term>
<term>Immune Evasion</term>
<term>Immunologic Memory</term>
<term>Killer Cells, Natural</term>
<term>Pneumonia, Viral</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Cryoelectron Microscopy</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Neutralization Tests</term>
<term>Vero Cells</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020<sup>1,2</sup>
. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32422645</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>583</Volume>
<Issue>7815</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</ArticleTitle>
<Pagination><MedlinePgn>290-295</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2349-y</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020<sup>1,2</sup>
. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName>
<ForeName>Dora</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Young-Jun</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beltramello</LastName>
<ForeName>Martina</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Walls</LastName>
<ForeName>Alexandra C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tortorici</LastName>
<ForeName>M Alejandra</ForeName>
<Initials>MA</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-2260-2577</Identifier>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bianchi</LastName>
<ForeName>Siro</ForeName>
<Initials>S</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-5100-8905</Identifier>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jaconi</LastName>
<ForeName>Stefano</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Culap</LastName>
<ForeName>Katja</ForeName>
<Initials>K</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-0956-0018</Identifier>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zatta</LastName>
<ForeName>Fabrizia</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Marco</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peter</LastName>
<ForeName>Alessia</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guarino</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spreafico</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cameroni</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Case</LastName>
<ForeName>James Brett</ForeName>
<Initials>JB</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7331-5511</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Rita E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Havenar-Daughton</LastName>
<ForeName>Colin</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-2880-3927</Identifier>
<AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Snell</LastName>
<ForeName>Gyorgy</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Telenti</LastName>
<ForeName>Amalio</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Virgin</LastName>
<ForeName>Herbert W</ForeName>
<Initials>HW</Initials>
<AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lanzavecchia</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Diamond</LastName>
<ForeName>Michael S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fink</LastName>
<ForeName>Katja</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Veesler</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-6019-8675</Identifier>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Corti</LastName>
<ForeName>Davide</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-5797-1364</Identifier>
<AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 GM120553</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN272201700059C</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>75N93019C00062</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Jul;583(7815):203-204</RefSource>
<PMID Version="1">32623442</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000920" MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32422645</ArticleId>
<ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId>
<ArticleId IdType="pii">10.1038/s41586-020-2349-y</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001232 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001232 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidFranceV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32422645 |texte= Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32422645" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidFranceV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |